Bakkt, Inc. ("Bakkt," or "the Company") (NYSE:BKKT) today announced that it has received the required Indian regulatory approvals in connection with its previously disclosed strategic investment in Transchem Limited (BSE: 500422) ("Transchem"). Following receipt of such approvals, Transchem has completed the allotment of 47,500,000 warrants to Bakkt, for which Bakkt paid approximately $9.4 million, representing 25% of the total subscription amount.